Liraglutide studies: 1,219 papers with results
Page 3 of 25
- Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study.
Nagaike H · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2019
Randomized controlled trial · 15 results
- Liraglutide in an Adolescent Population with Obesity: A Randomized, Double-Blind, Placebo-Controlled 5-Week Trial to Assess Safety, Tolerability, and Pharmacokinetics of Liraglutide in Adolescents Aged 12-17 Years.
Danne T · The Journal of pediatrics · 2017
Randomized controlled trial · 9 results
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
Hermansen K · Diabetes, obesity & metabolism · 2013
Randomized controlled trial · 10 results
- Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
Faurschou A · Journal of the European Academy of Dermatology and Venereology : JEADV · 2015
Randomized controlled trial · 7 results
- Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
Frandsen CS · Diabetes, obesity & metabolism · 2017
Randomized controlled trial · 7 results
- Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity.
Valenzuela-Vallejo L · Metabolism: clinical and experimental · 2022
Randomized controlled trial · 3 results
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
Farr OM · Diabetologia · 2016
Randomized controlled trial · 5 results
- Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial.
Bouchi R · Endocrine journal · 2017
Randomized controlled trial · 9 results
- Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Jensterle M · BMC endocrine disorders · 2017
Randomized controlled trial · 8 results
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Garber A · Lancet (London, England) · 2009
Randomized controlled trial · 4 results
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
Lundgren JR · The New England journal of medicine · 2021
Randomized controlled trial · 14 results
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
Yan J · Hepatology (Baltimore, Md.) · 2019
Randomized controlled trial · 10 results
- Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.
Madsbad S · Diabetes care · 2004
Randomized controlled trial · 7 results
- Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
Jensterle Sever M · European journal of endocrinology · 2014
Randomized controlled trial · 15 results
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.
Guo W · Diabetes research and clinical practice · 2020
Randomized controlled trial · 10 results
- Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.
Nauck MA · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2006
Randomized controlled trial · 7 results
- Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Jensterle M · Journal of ovarian research · 2015
Randomized controlled trial · 7 results
- Efficacy and safety of glucagon-like peptide-1/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study.
Alba M · Clinical obesity · 2021
Randomized controlled trial · 1 result
- Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.
Idorn T · Diabetes care · 2016
Randomized controlled trial · 7 results
- A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin.
Lingvay I · Diabetes care · 2018
Randomized controlled trial · 7 results
- Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.
Azar ST · Diabetes, obesity & metabolism · 2016
Randomized controlled trial · 6 results
- Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits.
Nauck M · Postgraduate medicine · 2009
Randomized controlled trial · 6 results
- Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K · Diabetes, obesity & metabolism · 2019
Randomized controlled trial · 12 results
- Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.
Caruso P · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 10 results
- A randomized phase I study of BI 1820237, a novel neuropeptide Y receptor type 2 agonist, alone or in combination with low-dose liraglutide in otherwise healthy men with overweight or obesity.
Beetz N · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 4 results
- One Year of Exercise After Weight Loss Increases Postprandial GLP-1 Secretion in Contrast to Usual Activity or GLP-1 Receptor Agonist Treatment.
Holt J · Obesity (Silver Spring, Md.) · 2026
Randomized controlled trial · 2 results
- Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio.
Kaneko M · The Annals of pharmacotherapy · 2018
Randomized controlled trial · 4 results
- Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.
Kaneko S · Journal of diabetes investigation · 2018
Randomized controlled trial · 4 results
- Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.
Krishnan K · Diabetes research and clinical practice · 2024
Randomized controlled trial · 8 results
- Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial.
Kiyosue A · Journal of diabetes investigation · 2018
Randomized controlled trial · 6 results
- Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
Takeshita Y · Journal of diabetes investigation · 2022
Randomized controlled trial · 9 results
- A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
Inoue Y · Journal of clinical pharmacology · 2015
Randomized controlled trial · 2 results
- Accounting for non-adherence: A re-analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results trial.
Sørensen KK · Clinical trials (London, England) · 2026
Randomized controlled trial · 9 results
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
Mann JFE · The New England journal of medicine · 2017
Randomized controlled trial · 4 results
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
The New England journal of medicine · 2022
Randomized controlled trial · 9 results
- The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes.
Nielsen R · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 7 results
- Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial.
Sandsdal RM · Cardiovascular diabetology · 2023
Randomized controlled trial · 6 results
- Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial.
Pandey A · Journal of cachexia, sarcopenia and muscle · 2024
Randomized controlled trial · 3 results
- Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial.
Zobel EH · BMJ open diabetes research & care · 2021
Randomized controlled trial · 8 results
- Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.
Rasmussen IKB · Diabetes, obesity & metabolism · 2021
Randomized controlled trial · 4 results
- Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation.
Bizino MB · Diabetologia · 2020
Randomized controlled trial · 8 results
- Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes.
Schmidt S · Diabetes, obesity & metabolism · 2022
Randomized controlled trial · 4 results
- Effects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.
Gutierrez de Piñeres V · Diabetes research and clinical practice · 2026
Randomized controlled trial · 11 results
- Physical Fitness with Exercise and GLP-1 Receptor Agonist Treatment Alone or Combined After Diet-Induced Weight Loss: A Secondary Analysis of a Randomized Controlled Trial in Adults with Obesity.
Jensen SBK · Sports medicine (Auckland, N.Z.) · 2026
Randomized controlled trial · 11 results
- The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
Richardson KM · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 9 results
- Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance: a prespecified secondary analysis of the S-LiTE trial.
Sandsdal RM · Nature metabolism · 2026
Randomized controlled trial · 12 results
- Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial.
Nauck MA · Diabetes care · 2018
Randomized controlled trial · 7 results
- Liraglutide pharmacokinetics and dose-exposure response in Asian subjects with Type 2 diabetes from China, India and South Korea.
Ingwersen SH · Diabetes research and clinical practice · 2015
Randomized controlled trial · 5 results
- Effect of weight loss and liraglutide on neutrophil gelatinase-associated lipocalin levels among individuals with overweight and knee osteoarthritis: Exploratory analyses of a randomized controlled trial.
Poulsen AS · Osteoarthritis and cartilage open · 2025
Randomized controlled trial · 1 result
- Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.
Jensen SBK · Nature communications · 2022
Randomized controlled trial · 4 results